Page 2 - Protein Engineering News Today

The global protein engineering market size is estimated to reach around USD 15.25 billion by 2032, increasing from USD 3.18 billion in 2022, According to...

Current information from the Federal Administration. All press releases from the Federal Administration, the departments and offices.

Mural Oncology plc spins out from Alkermes plc with $275 million in committed funding, providing a cash runway projected into 4Q 2025 Company’s lead product candidate – nemvaleukin alfa – being developed to treat a wide range of solid tumors – is currently in two potentially registrational clinical trials, both with readouts expected in 1Q 2025 Mural is also advancing engineered therapies targeting interleukin-18 and interleukin-12 with plans to nominate a development...

<p><strong>Karl Klose</strong>, director of The South Texas Center for Emerging Infectious Diseases (STCEID) and the Robert J. Kleberg, Jr. and Helen C. Kleberg College of Sciences Endowed Professor, coauthored a research article with <strong>Cameron Lloyd </strong>’23, a UTSA doctoral student who graduated in August with a Ph.D. in molecular microbiology and immunology under the guidance of Klose. </p> <p>According t...

Karl Klose, director of The South Texas Center for Emerging Infectious Diseases (STCEID) and the Robert J. Kleberg, Jr. and Helen C. Kleberg College of Sciences Endowed Professor, coauthored a research article with Cameron Lloyd '23, a UTSA doctoral student who graduated in August with a Ph.D. in molecular microbiology and immunology under the guidance of Klose.

A potent anti-cancer therapy has been created using Nobel prize-winning "click chemistry", where molecules click together like LEGO bricks, in a new study by UCL and Stanford University researchers.

Cra​​​​​​​dle, the platform that helps scientists to design and program proteins, today published the findings of its first BioDeveloper survey, exploring the methods and priorities of biodevelopers to build a picture of trends within the synthetic biology sector.

Affordable two-chip Beacon Select system to broaden customer access to innovative high throughput, function-first antibody discovery capabilities.

Through a recent platform demonstration project, LabGenius’ machine learning-driven lead optimisation capability delivered dozens of novel T-cell engagers with best-in-class killing selectivity.

Affordable two-chip Beacon Select system to broaden customer access to innovative high throughput, function-first antibody discovery capabilities EMERYVILLE, Calif., May 15, 2023 /PRNewswire/ --... | May 15, 2023